NLRP3 and head and neck squamous cell carcinoma: To evaluated the potential role of inflammation on CSCs markers during SCCHN progression and the use of the novel anti-inflammatory NLRP3 inflammasome inhibitor MCC950 arising de novo in 2cKO mouse SCCHN model.